Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Oligoprogressive 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × DEAE-Dextran × Clear all
NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡